Literature DB >> 24963576

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Liang Shen, Hong-Fang Ji.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24963576     DOI： 10.1056/NEJMc1404894

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.

Authors:  Vivek Subbiah; David S Hong; Funda Meric-Bernstam
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-25       Impact factor: 11.205

Review 2.  Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity.

Authors:  Pooja Gupta; Tavneet Kaur Makkar; Lavisha Goel; Monika Pahuja
Journal:  Immunol Res       Date:  2022-07-20       Impact factor: 4.505

3.  Neurological complications of new chemotherapy agents.

Authors:  Alicia M Zukas; David Schiff
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

Review 4.  A comprehensive review of protein kinase inhibitors for cancer therapy.

Authors:  Radhamani Kannaiyan; Daruka Mahadevan
Journal:  Expert Rev Anticancer Ther       Date:  2018-10-09       Impact factor: 4.512

Review 5.  Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer.

Authors:  Stavros Gkolfinopoulos; Giannis Mountzios
Journal:  Ann Transl Med       Date:  2018-04

6.  The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.

Authors:  Sha Fu; Ying Liang; Yong-Bin Lin; Fang Wang; Ma-Yan Huang; Zi-Chen Zhang; Jing Wang; Wen-Jian Cen; Jian-Yong Shao
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

7.  Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.

Authors:  Rui Wang; Xiaolan Deng; Yuichiro Yoshioka; Theodore Vougiouklakis; Jae-Hyun Park; Takehiro Suzuki; Naoshi Dohmae; Koji Ueda; Ryuji Hamamoto; Yusuke Nakamura
Journal:  Cancer Sci       Date:  2017-06       Impact factor: 6.716

Review 8.  Fluorescence in situ hybridization in surgical pathology: principles and applications.

Authors:  Liang Cheng; Shaobo Zhang; Lisha Wang; Gregory T MacLennan; Darrell D Davidson
Journal:  J Pathol Clin Res       Date:  2017-02-23

9.  Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway.

Authors:  Hui Chen; Qiang Zhang; Yu Zhang; Bin Jia; Bin Zhang; Changli Wang
Journal:  Onco Targets Ther       Date:  2018-11-26       Impact factor: 4.147

Review 10.  Emerging non-invasive detection methodologies for lung cancer.

Authors:  Zhen Li; Jinian Shu; Bo Yang; Zuojian Zhang; Jingyun Huang; Yang Chen
Journal:  Oncol Lett       Date:  2020-03-12       Impact factor: 2.967
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.